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Benign prostatic hyperplasia.
Part 1—Diagnosis
Timothy J Wilt,1 James N’Dow2
Lowerurinary tract symptoms inoldermenarecommon
and bothersome, leading to considerable use of health-
care services.1 2 Symptoms may reflect obstructive
voiding (weak urine flow, hesitancy, straining, and
incomplete emptying) or bladder storage problems
(frequency, urgency, and nocturia). Lower urinary tract
symptoms are often considered to be due to benign
prostatic hyperplasia (BPH) or benign prostatic enlarge-
ment.However, suchsymptomsarecommoninwomen,
as well as in men with prostate glands that are not
enlarged.34The symptomscanbecausedbyoveractivity
of the bladder’s detrusor muscle, non-urological condi-
tions, medications, or lifestyle factors. This article
provides evidence to guide primary care doctors in the
diagnosis of men with lower urinary tract symptoms,
with an emphasis on BPH. A second article, to be
published soon, will focus on management.
What causes lower urinary tract symptoms due to BPH?
The pathophysiology of benign prostatic enlargement
involves hyperplasia of the epithelial and stromal
components of the prostate gland, which leads to
progressive obstruction of urine flow and increased
activity of the detrusor muscle.5 These secondary
urodynamic changes are thought to result in the typical
symptoms of bladder storage such as frequency and
nocturia and voiding symptoms such as poor flow and
intermittent stream. For simplicity, these complaints are
grouped together as lower urinary tract symptoms.
Although the precise relation between symptoms,
prostate enlargement, and obstruction is not certain,
removal of prostatic tissue in affected men improves
symptoms, urodynamic function, and quality of life.
What is the prevalence and natural course of lower
urinary tract symptoms?
BPH is the most common benign neoplasia in men.
Lower urinary tract symptoms due toBPHare regarded
as a chronic condition that increases in frequency and
severity with age. In men 50 years or older in England,
Scotland, and Wales, 41% described symptoms classed
as moderate to severe, but only 18% reported that they
had received a clinical diagnosis of BPH. Quality of life
and general health status decreased as severity of
symptoms increased; however, only about 1 in 10
respondents was aware of the availability of prescription
drugs or surgical options for BPH.6 Storage and voiding
symptoms were self reported by 51% and 26%
respectively of men aged 39 and older from five
European countries, with the prevalence of reporting
increasing with age (table).3 Results from other national
surveys suggest that despite being common and bother-
some, lower urinary tract symptoms often go undiag-
nosed or untreated.78 Mild symptoms do not greatly
affect qualityof life, but the impact of severe symptoms is
similar to chronic conditions such as hypertension,
diabetes, angina, and gout.9
Few risk factors exist for BPH, other than age and
possibly obesity.10 Slow progression of symptoms and
bothersome effects of these symptoms are common
features of BPH. About 14% of men with moderate to
severe symptoms had clinically noticeable worsening of
their symptoms during five years of follow-up.11 More
serious complications—such as acute urinary retention
(1-3%over fiveyears), renal insufficiency, or theneed for
surgical intervention—are uncommon.12-14 In a rando-
mised comparison with transurethral resection of the
Sources and selections criteria
We searched Medline and the Cochrane Library up to
November 2007 for randomised trials, systematic
reviews, evidence reports, and recent evidence based
guidelines from the American Urological Association,
European Urological Association, and the National
Institute for Health and Clinical Excellence.
Unanswered questions
 Which assessment tools and diagnostic tests give useful prediction of treatment
response?
 Can the contributions of (a) benign prostatic hyperplasia and (b) dysfunction of the
detrusor muscle to lower urinary tract symptoms be differentiated?
 Benign prostatic hyperplasia and dysfunction of the detrusor muscle both contribute to
lower urinary tract symptoms, but how can the two causes be differentiated?
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prostate, a quarter of men with moderate symptoms
assigned to receive advice alone had prostate surgery for
progressive symptomsorother signsofBPHprogression
during a three year follow-up15 (fig 1). However, in a
more recent study of men with benign prostatic
enlargement and moderate to severe baseline symp-
toms, only 6% of men receiving placebo had acute
urinary retention or needed BPH surgery after five
years11 (fig 2). Therefore, the vast majority of men even
with moderate to severe symptoms do not need surgery
for many years.
What diagnostic tests should be used routinely in men
with lower urinary tract symptoms?
History, physical examination, and laboratory and
urodynamic tests are used to identify the presence,
severity, and aetiology of lower urinary tract symptoms
and to guide treatment, including the need for referral to
urologists. History can determine if the symptoms are
caused by other medical conditions (poorly controlled
diabetes, neurological disorders, urinary tract infections,
chronic abacterial prostatitis, overactive bladder), med-
ications, (diuretics, anticholinergics, antidepressants),16
or lifestyle factors (caffeine, alcohol, excess intake of
liquids).
A validated questionnaire—usually the international
prostate symptoms scale17—is a simple and reliable
method to assess the presence, type, and severity of
symptoms and the response to treatment (box).Comple-
tionof thequestionnaire yields a total score ranging from
0 to 35 (1-7 for mild symptoms; 8-19 for moderate; and
20-35 for severe). In the questionnaire, one question
(about how men feel about their current urinary
symptoms) yields a score for quality of life (0=delighted,
6=terrible). Other health status questions directly ask
how bothersome urinary symptoms are. Although
symptom severity correlates with scores for quality of
life and how bothersome symptoms are, variation may
exist. For example, some men with relatively minor
symptoms feel terrible or find their symptoms very
bothersome, whereas other men with severe symptoms
may be bothered by themmuch.
Patient response on the quality of life question is a
strong predictor for determining if interventions are
indicated.17 The presence of urinary incontinence,
retention, haematuria, dysuria, or acute change in
symptoms can indicate other conditions or complica-
tionsofBPH.Thesepatientsoftenneed tobereferred toa
urologist for further evaluation even if they have not
reported their symptoms as bothersome. Abdominal
examination to detect palpable bladder is indicated if
obstruction of the bladder outlet is suspected. Fear that
lower urinary tract symptomsmaybe causedbyprostate
cancer is a major reason that men consult their doctor.18
However, men can be reassured that those with lower
urinary tract symptoms are not at higher risk of having
prostate cancer than men without these symptoms.1920
Therefore, although measurement of prostate specific
antigen and digital rectal examination arewidely used to
try to detect cancer, these approaches are not routinely
indicated. Levels of prostate specific antigen are
associated with prostate volume; when combined with
symptom severity and how bothersome the symptoms
are, the antigen levels can be helpful in estimating
treatment effectiveness. Widespread measurement of
prostate specific antigen is likely to lead to increased
falsely abnormal findings and subsequent diagnostic
tests (see www.cancerscreening.nhs.uk/prostate/).
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Fig 1 Severity of symptomsafter three years of follow-up inmen
with benign prostatic hyperplasia treated with transurethral
resection of the prostate or watchful waiting, relative to how
bothersome their symptoms were at baseline. Adapted from
Wasson et al
International prostate symptom scale
Scoring system
Askthepatientsevenquestions (below)abouthisurinarysymptoms.Answersareonascale
of0-5,dependingonseverityof theproblem.For the first sixquestions thechoiceofanswers
is: not at all (score0); less thanone time in five (1); less thanhalf the time (2); abouthalf the
time (3); more than half the time (4); almost always (5). For the final question, the choices
are: never (0); once (1); twice (2); three times (3); four times (4); five ormore times (5). Add
the scores to give the total score and thus the severity category for symptoms (mild <8;
moderate 8-19; severe 20-35). A further question—on quality of life (below)—produces a
quality of life score
Questions
1 Over the past month, how often have you had a sensation of not emptying your bladder
completely after you finished urinating?
2 Over thepastmonth,howoftenhaveyouhadtheurgetourinateagain less thantwohours
after you finished urinating?
3 Over the past month, how often have you found you stopped and started again several
times when you urinated?
4 Over the past month, how often have you found it difficult to postpone urination?
5 Over the past month, how often have you had a weak urinary stream? (Please compare
with your stream size at age 30)
6 Over the past month, how often have you had to push or strain to begin urination?
7 Over the past month, how many times did you most typically get up to urinate from the
time you went to bed at night until the time you got up in the morning?
Question on quality of life in relation to urinary symptoms
If you were to spend the rest of your life with your urinary condition the way it is now, how
wouldyoufeelabout that?Delighted(0),pleased(1),mostlysatisfied(2),mixedfeelings (3),
mostly dissatisfied (4), unhappy (5), terrible (6)
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Evidence based guidelines indicate that diagnostic
studies are not usually required or helpful for primary
care management.2122 Optional evaluations (based on
unique patient situations or on a general practitioner’s
preferences) include ultrasonography for estimation of
residual urine volume; urinary diaries (for recording
frequencyandvolumeofvoiding)particularly ifnocturia
is prominent; urine analysis to exclude infection; and
measurement of serum creatinine concentration if renal
insufficiency or urinary retention is suspected. Primary
care physicians may have access to, and skills to
interpret, urodynamic testing such as uroflowmetry,
although such testing is often done by urologists.
What additional diagnostic tests are used in secondary
care?
The reasons for conducting additional diagnostic tests
include patient reassurance or explanation, objective
assessment of symptoms, diagnostic precision, ranking
of treatment options, and prediction of treatment
outcome.
Diaries
Completionof a voidingdiary by the patient over a few
days gives an assessment of storage symptoms such as
nocturia, gives information on daily bladder capacity,
and can indicate other causes of lower urinary tract
symptoms, such as nocturnal polyuria or excessive
fluid intake. Diaries can also be used as a basis for
educating the patient about self management or for
suggesting alternative treatments such as diuretics.23
Uroflowmetry
Objectivemeasurement of variables such asmaximum
flow rate and volume of residual urine after voiding
gives useful information onmicturition, and the results
can to some extent predict the likelihood of disease
progression and response to treatment. For example, a
low flow rate suggests obstruction and may be
associated with a better outcome after transurethral
resection of the prostate, although underactivity of the
detrusor muscle can result in the same findings. It is
advisable to take serial flowmeasurements (at least two
of voided volumes over 150 ml) to ensure that
interpretation is based on a representative void.22
Bladder pressure studies
Pressure measurement (cystometry) during bladder
filling and voiding defines several urodynamic abnorm-
alities, including overactivity (or underactivity) of the
detrusor muscle and obstruction of the bladder outlet.
The results are useful in predicting the response to
treatment such as antimuscarinics for overactivity of the
detrusor muscle and transurethral resection of the
prostate for obstruction of the bladder outlet. They also
providean importantbaseline formenwho fail tobenefit
fromsurgery.Despite these advantages the clinical value
of cystometry is debated,mainly because of the need for
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Fig 2 Cumulative incidence of acute urinary retention and
invasive therapy for BPH. Adapted from McConnell et al
Ongoing research
 Characterisation of genetic and molecular events linked with symptomatic benign
prostatic hyperplasia
 The National Collaborating Centre for Acute Care hosted by the Royal College of Surgeons
ofEnglandhasrecentlybeencommissionedbytheNational InstituteofHealthandClinical
Excellence (NICE) to develop an evidence based clinical guideline on themanagement of
benign prostatic hyperplasia. Their recommendations should be available in 2009
Percentage ofmenwith lower urinary tract symptoms*
Urinary symptoms
Age (years)
All ages≤39 40-59 ≥60
Storage
Any storage symptom 38 51 74 51
Nocturia at least once a night 34 48 72 49
Urgency 7 9 19 11
Frequency 5 6 11 7
Any urinary incontinence 2 5 10 5
Voiding
Any voiding symptom 20 24 37 26
Intermittency 6 8 14 8
Slow stream 4 7 19 9
Strain 4 7 10 7
Terminal dribbling 12 13 19 14
*Adapted from Irwin et al.3
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catheterisation; cystometry is generally confined tomen
with complicating factors such as urge incontinence or
severe comorbidity, where accurate prediction of out-
come is of greater importance.2224
Urinary tract imaging
Imaging of the urinary tract, apart from ultrasound
estimation of residual urine, is no longer considered
routine for men with lower urinary tract symptoms.
Ultrasound examination of the kidneys and bladder
can be useful for identifying stones inmenwith urinary
tract infections and for seeing tumours if haematuria is
detected by urine analysis. Detected abnormalities
usually require further imaging by computed tomo-
graphy or intravenous urography. Estimation of
prostate size by abdominal or transrectal ultrasono-
graphy may help to predict benefit from combined
treatment with α blockers and 5α reductase inhibitors
and may also guide surgical management.11 21 22
Urethrocystoscopy
Visual inspection of the urethra and bladder is
important in men with dysuria or haematuria as it can
showmucosal abnormalities such as bladder tumours.
Inspection may also be necessary for differentiating
urethral strictures from prostatic causes of obstruction
in younger men or those who have had previous
transurethral surgery.
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Additional educational resources
 PatientPlus (www.patient.co.uk/showdoc/40002437/)—Comprehensive, free, up to
date health information as provided by general practitioners to patients during
consultations
 Foundation for Informed Medical Decision Making (www.fimdm.org)—Provides
information to help patients make sound decisions affecting their health and wellbeing
 Health Dialog (www.healthdialog.com)—Provides care management and analytical
services
 Cochrane Library (www.cochrane.org)—Publishes systematic reviews of the effects of
healthcare interventions
SUMMARY POINTS
Lower urinary tract symptoms are bothersome yet often under-reported by older men
Symptom severity generally progresses over time but is rarely life threatening
Many clinical and lifestyle factors can cause or worsen the symptoms but can bemodified by
simple interventions
Asking about how bothersome the symptoms are and how they affect the patient’s quality of
life is useful for considering whether to suggest additional treatment
Benign prostatic hyperplasia does not increase risk of prostate cancer but is associated with
higher levels of prostate specific antigen
These levels are associated with prostate volume and may be useful when combined with
symptom and health status measures for assessing potential effectiveness of treatment
options
Mostmencanbeassessedand treatedbyprimary care clinicianson thebasis of the severity of
their symptoms and how bothersome they are
Additional diagnostic evaluations include diaries, uroflowmetry, bladder pressure studies,
urinary tract imaging, and urethrocystoscopy
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